Size does not matter: Commensal microorganisms forge tumorpromoting inflammation and anti-tumor immunity

Oncoscience

Volumn 2, Issue 3, 2015, Pages 239-246

  Rutkowski, Melanie R ^a   Conejo Garcia, Jose R ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Cancer; Gamma delta T cell; Inflammation; Microbiota; TLR5

Indexed keywords

EID: 84958539780     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.145     Document Type: Article

References (52)

1. Mazmanian SK and Kasper DL. The love-hate relationship between bacterial polysaccharides and the host immune system. Nat Rev Immunol. 2006; 6(11):849-858.
2. Tlaskalova-Hogenova H, Stepankova R, Kozakova H, Hudcovic T, Vannucci L, Tuckova L, Rossmann P, Hrncir T, Kverka M, Zakostelska Z, Klimesova K, Pribylova J, Bartova J, Sanchez D, Fundova P, Borovska D, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011; 8(2):110-120.
3. Gagliani N, Hu B, Huber S, Elinav E and Flavell RA. The fire within: microbes inflame tumors. Cell. 2014; 157(4):776-783.
4. Mazmanian SK, Round JL and Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008; 453(7195):620-625.
5. Umesaki Y, Setoyama H, Matsumoto S and Okada Y. Expansion of alpha beta T-cell receptor-bearing intestinal intraepithelial lymphocytes after microbial colonization in germ-free mice and its independence from thymus. Immunology. 1993; 79(1):32-37.
6. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE and Relman DA. Diversity of the human intestinal microbial flora. Science. 2005; 308(5728):1635-1638.
7. Macpherson AJ and Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004; 4(6):478-485.
8. Huang T, Wei B, Velazquez P, Borneman J and Braun J. Commensal microbiota alter the abundance and TCR responsiveness of splenic naive CD4+ T lymphocytes. Clin Immunol. 2005; 117(3):221-230.
9. Ostman S, Rask C, Wold AE, Hultkrantz S and Telemo E. Impaired regulatory T cell function in germ-free mice. Eur J Immunol. 2006; 36(9):2336-2346.
10. Probert CS, Williams AM, Stepankova R, Tlaskalova-Hogenova H, Phillips A and Bland PW. The effect of weaning on the clonality of alpha beta T-cell receptor T cells in the intestine of GF and SPF mice. Dev Comp Immunol. 2007; 31(6):606-617.
11. Guy-Grand D, Cerf-Bensussan N, Malissen B, Malassis-Seris M, Briottet C and Vassalli P. Two gut intraepithelial CD8+ lymphocyte populations with different T cell receptors: a role for the gut epithelium in T cell differentiation. J Exp Med. 1991; 173(2):471-481.
12. Shaw MH, Kamada N, Kim YG and Nunez G. Microbiotainduced IL-1beta, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med. 2012; 209(2):251-258.
13. Like AA, Rossini AA, Guberski DL, Appel MC and Williams RM. Spontaneous diabetes mellitus: reversal and prevention in the BB/W rat with antiserum to rat lymphocytes. Science. 1979; 206(4425):1421-1423.
14. Kohashi O, Kuwata J, Umehara K, Uemura F, Takahashi T and Ozawa A. Susceptibility to adjuvant-induced arthritis among germfree, specific-pathogen-free, and conventional rats. Infect Immun. 1979; 26(3):791-794.
15. Feng T, Wang L, Schoeb TR, Elson CO and Cong Y. Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis. J Exp Med. 2010; 207(6):1321-1332.
16. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y and Weiser JN. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med. 2010; 16(2):228-231.
17. Abt MC, Osborne LC, Monticelli LA, Doering TA, Alenghat T, Sonnenberg GF, Paley MA, Antenus M, Williams KL, Erikson J, Wherry EJ and Artis D. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity. 2012; 37(1):158-170.
18. Oh JZ, Ravindran R, Chassaing B, Carvalho FA, Maddur MS, Bower M, Hakimpour P, Gill KP, Nakaya HI, Yarovinsky F, Sartor RB, Gewirtz AT and Pulendran B. TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity. 2014; 41(3):478-492.
19. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM and Sears CL. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009; 15(9):1016-1022.
20. Eisenring M, vom Berg J, Kristiansen G, Saller E and Becher B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol. 11(11):1030-1038.
21. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, Dai RM, Kiu H, Cardone M, Naik S, Patri AK, Wang E, et al. Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment. Science. 2013; 342.
22. Viaud S, Saccheri F, Mignot Gg, Yamazaki T, Daillvre R, Hannani D, Enot D, Pfirschke C, Engblom C, Pittet M, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther P-L, Eberl Gr, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (New York, NY). 2013; 342(6161):971-976.
23. Viaud S, Daillere R, Boneca IG, Lepage P, Pittet MJ, Ghiringhelli F, Trinchieri G, Goldszmid R and Zitvogel L. Harnessing the intestinal microbiome for optimal therapeutic immunomodulation. Cancer Res. 2014; 74(16):4217-4221.
24. Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L and Trinchieri G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol. 2015; 45(1):17-31.
25. Rutkowski MR, Stephen TL, Svoronos N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A, Brencicova E, Escovar-Fadul X, Nguyen JM, Cadungog MG, Zhang R, Salatino M, Tchou J, Rabinovich GA and Conejo-Garcia JR. Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation. Cancer cell. 2015; 27(1):27-40.
26. Pfirschke C, Garris C and Pittet MJ. Common TLR5 Mutations Control Cancer Progression. Cancer cell. 2015; 27(1):1-3.
27. Elinav E, Nowarski R, Thaiss C, Hu B, Jin C and Flavell R. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nature reviews Cancer. 2013; 13(11):759-771.
28. Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, Eisenbarth SC and Flavell RA. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A. 2010; 107(50):21635-21640.
29. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, Herfarth HH, Jobin C and Ting JP. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010; 207(5):1045-1056.
30. Wolf KJ, Daft JG, Tanner SM, Hartmann R, Khafipour E and Lorenz RG. Consumption of acidic water alters the gut microbiome and decreases the risk of diabetes in NOD mice. J Histochem Cytochem. 2014; 62(4):237-250.
31. Sofi MH, Gudi R, Karumuthil-Melethil S, Perez N, Johnson BM and Vasu C. pH of drinking water influences the composition of gut microbiome and type 1 diabetes incidence. Diabetes. 2014; 63(2):632-644.
32. Letran SE, Lee SJ, Atif SM, Flores-Langarica A, Uematsu S, Akira S, Cunningham AF and McSorley SJ. TLR5-deficient mice lack basal inflammatory and metabolic defects but exhibit impaired CD4 T cell responses to a flagellated pathogen. J Immunol. 2011; 186(9):5406-5412.
33. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE and Gewirtz AT. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010; 328(5975):228-231.
34. Vijay-Kumar M, Sanders C, Taylor R, Kumar A, Aitken J, Sitaraman S, Neish A, Uematsu S, Akira S, Williams I and Gewirtz A. Deletion of TLR5 results in spontaneous colitis in mice. The Journal of clinical investigation. 2007; 117(12):3909-3921.
35. Carvalho F, Nalbantoglu I, Ortega-Fernandez S, Aitken J, Su Y, Koren O, Walters W, Knight R, Ley R, Vijay-Kumar M and Gewirtz A. Interleukin-1β (IL-1β) promotes susceptibility of Toll-like receptor 5 (TLR5) deficient mice to colitis. Gut. 2012; 61(3):373-384.
36. Casanova JL, Abel L and Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol. 29:447-491.
37. Hawn TR, Verbon A, Lettinga KD, Zhao LP, Li SS, Laws RJ, Skerrett SJ, Beutler B, Schroeder L, Nachman A, Ozinsky A, Smith KD and Aderem A. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med. 2003; 198(10):1563-1572.
38. Hugot JP, Zaccaria I, Cavanaugh J, Yang H, Vermeire S, Lappalainen M, Schreiber S, Annese V, Jewell DP, Fowler EV, Brant SR, Silverberg MS, Cho J, Rioux JD, Satsangi J and Parkes M. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol. 2007; 102(6):1259-1267.
39. Pothlichet J, Burtey A, Kubarenko AV, Caignard G, Solhonne B, Tangy F, Ben-Ali M, Quintana-Murci L, Heinzmann A, Chiche JD, Vidalain PO, Weber AN, Chignard M and Si-Tahar M. Study of human RIG-I polymorphisms identifies two variants with an opposite impact on the antiviral immune response. PLoS One. 2009; 4(10):e7582.
40. Adler J, Rangwalla SC, Dwamena BA and Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol. 106(4):699-712.
41. Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Gewirtz AT, Ahonen CL and Conejo-Garcia JR. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 2009; 69(18):7329-7337.
42. Ubeda C, Lipuma L, Gobourne A, Viale A, Leiner I, Equinda M, Khanin R and Pamer EG. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. J Exp Med. 2012; 209(8):1445-1456.
43. Ivanov, II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009; 139(3):485-498.
44. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, Kim S, Fritz JV, Wilmes P, Ueha S, Matsushima K, Ohno H, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013; 500(7461):232-236.
45. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015; 517(7533):205-208.
46. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH and Wang RF. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007; 27(2):334-348.
47. Rubinstein N, Alvarez M, Zwirner N, Toscano M, Ilarregui J, Bravo A, Mordoh J, Fainboim L, Podhajcer O and Rabinovich G. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumorimmune privilege. Cancer cell. 2004; 5(3):241-251.
48. Croci DO, Cerliani JP, Dalotto-Moreno T, Mendez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, Garcia-Vallejo JJ, Ouyang J, Mesri EA, Junttila MR, Bais C, Shipp MA, Salatino M and Rabinovich GA. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014; 156(4):744-758.
49. Rabinovich GA. Galectin-1 as a potential cancer target. Br J Cancer. 2005; 92(7):1188-1192.
50. Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD, Zwirner NW, Poirier F, Riley EM, Baum LG and Rabinovich GA. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol. 2007; 8(8):825-834.
51. Stephen TL, Rutkowski MR, Allegrezza MJ, Perales-Puchalt A, Tesone AJ, Svoronos N, Nguyen JM, Sarmin F, Borowsky ME, Tchou J and Conejo-Garcia JR. Transforming growth factor beta-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity. 2014; 41(3):427-439.
52. Cullen TW, Schofield WB, Barry NA, Putnam EE, Rundell EA, Trent MS, Degnan PH, Booth CJ, Yu H and Goodman AL. Gut microbiota. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science. 2015; 347(6218):170-175.